0102030405
Company News
Good News | T&L Cell Therapy Key Materials Have Been Registered with Fda Dmf, Helping Your Drug Application Process
2024-06-28
Recently, Beijing T&L Biotechnology Ltd. (hereinafter referred to as "T&L") received a confirmation letter from the US Food and Drug Administration (hereinafter referred to as "FDA"), stating that the company's key raw materials for cell therapy drugs, CD3 monoclonal antibody, and T cell sorting activation magnetic beads, have officially completed the DMF type II filing with the US FDA.